|
[1]
|
Liu, R., Han, C., Wu, D., Xia, X., Gu, J., Guan, H., Shan, Z. and Teng, W. (2015) Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. BioMed Research International, 2015, Article ID: 762820. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Levy, G.D., Rashid, N., Niu, F. and Cheetham, T.C. (2014) Effect of Urate-Lowering Therapies on Renal Disease Progression in Patients with Hyperuricemia. The Journal of Rheumatology, 41, 955-962. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wu, N., Xia, J., Chen, S., Yu, C., Xu, Y., Xu, C., Yan, T., Li, N., Liu, Y. and Pan, X.F. (2021) Serum Uric Acid and Risk of Incident Chronic Kidney Disease: A National Cohort Study and Updated Meta-Analysis. Nutrition & Metabolism, 18, 94. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Nakayama, S., Satoh, M., Tatsumi, Y., Murakami, T., Muroya, T., Hirose, T., Ohkubo, T., Mori, T., Hozawa, A. and Metoki, H. (2021) Detailed Association between Serum Uric Acid Levels and the Incidence of Chronic Kidney Disease Stratified by Sex in Middle-Aged Adults. Atherosclerosis, 330, 107-113. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Nashar, K. and Fried, L.F. (2012) Hyperuricemia and the Progression of Chronic Kidney Disease: Is Uric Acid a Marker or an Independent Risk Factor? Advances in Chronic Kidney Disease, 19, 386-391. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Jordan, D.M., Choi, H.K., Verbanck, M., Topless, R., Won, H.H., Nadkarni, G., Merriman, T.R. and Do, R. (2019) No Causal Effects of Serum Urate Levels on the Risk of Chronic Kidney Disease: A Mendelian Randomization Study. PLoS Medicine, 16, e1002725. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Knauf, F., Asplin, J.R., Granja, I., Schmidt, I.M., Moeckel, G.W., David, R.J., Flavell, R.A. and Aronson, P.S. (2013) NALP3-Mediated Inflammation Is a Principal Cause of Progressive Renal Failure in Oxalate Nephropathy. Kidney International, 84, 895-901. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
So, A.K. and Martinon, F. (2017) Inflammation in Gout: Mechanisms and Therapeutic Targets. Nature Reviews. Rheumatology, 13, 639-647. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Jung, S.W., Kim, S.M., Kim, Y.G., Lee, S.H. and Moon, J.Y. (2020) Uric Acid and Inflammation in Kidney Disease. American Journal of Physiology. Renal Physiology, 318, F1327-F1340. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Fan, S., Zhang, P., Wang, A. Y., Wang, X., Wang, L., Li, G. and Hong, D. (2019) Hyperuricemia and Its Related Histopathological Features on Renal Biopsy. BMC Nephrology, 20, Article No. 95. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lee, T.H., Chen, J.J., Wu, C.Y., Yang, C.W. and Yang, H.Y. (2021) Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy. Diagnostics (Basel, Switzerland), 11, 1674. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Berry, C.E. and Hare, J.M. (2004) Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanisms and Pathophysiological Implications. The Journal of Physiology, 555, 589-606. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Chan, H.L., Ku, G. and Khoo, O.T. (1977) Allopurinol Associated Hypersensitivity Reactions: Cutaneous and Renal Manifestations. Australian and New Zealand Journal of Medicine, 7, 518-522. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
中国医师协会肾脏内科医师分会. 中国肾脏疾病高尿酸血症诊治的实践指南(2017版) [J]. 中华医学杂志, 2017, 97(25): 1927-1936. [Google Scholar] [CrossRef]
|
|
[15]
|
Kim, S.C., Newcomb, C., Margolis, D., Roy, J. and Hennessy, S. (2013) Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study. Arthritis Care & Research, 65, 578-584. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Khanna, D., Fitzgerald, J.D., Khanna, P.P., Bae, S., Singh, M.K., Neogi, T., Pillinger, M.H., Merill, J., Lee, S., Prakash, S., Kaldas, M., Gogia, M., Perez-Ruiz, F., Taylor, W., Lioté, F., Choi, H., Singh, J.A., Dalbeth, N., Kaplan, S., Niyyar, V. and American College of Rheumatology (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research, 64, 1431-1446. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Khosravan, R., Grabowski, B.A., Wu, J.T., Joseph-Ridge, N. and Vernillet, L. (2006) Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects. Clinical Pharmacokinetics, 45, 821-841. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., Shibagaki, Y., Iimuro, S., Imai, N., Kuwabara, M., Hayakawa, H., Ohtsu, H., Ohashi, Y. and FEATHER Study Investigators (2018) Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 72, 798-810. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Li, S., Yang, H., Guo, Y., Wei, F., Yang, X., Li, D., Li, M., Xu, W., Li, W., Sun, L., Gao, Y. and Wang, Y. (2016) Comparative Efficacy and Safety of Urate-Lowering Therapy for the Treatment of Hyperuricemia: A Systematic Review and Network Meta-Analysis. Scientific Reports, 6, Article No. 33082. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Dincer, H.E., Dincer, A.P. and Levinson, D.J. (2002) Asymptomatic Hyperuricemia: To Treat or Not to Treat. Cleveland Clinic Journal of Medicine, 69, 594-608. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Nakata, T., Ikeda, S., Koga, S., Yonekura, T., Tsuneto, A., Doi, Y., Fukae, S., Minami, T., Kawano, H. and Maemura, K. (2020) Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia. International Heart Journal, 61, 984-992. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Hanvivadhanakul, P., Akkasilpa, S. and Deesomchok, U. (2002) Efficacy of Benzbromarone Compared to Allopurinol in Lowering Serum Uric Acid Level in Hyperuricemic Patients. Journal of the Medical Association of Thailand, 85, S40-S47.
|
|
[23]
|
Lee, M.H., Graham, G.G., Williams, K.M. and Day, R.O. (2008) A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout. Was Its Withdrawal from the Market in the Best Interest of Patients? Drug Safety, 31, 643-665. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
李鑫德, 李长贵. 促进尿酸分解药物的疗效与安全性评价[J]. 药品评价, 2015(7): 55-60. [Google Scholar] [CrossRef]
|
|
[25]
|
Ramazzina, I., Folli, C., Secchi, A., Berni, R. and Percudani, R. (2006) Completing the Uric Acid Degradation Pathway through Phylogenetic Comparison of Whole Genomes. Nature Chemical Biology, 2, 144-148. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Pascart, T. and Richette, P. (2018) Investigational Drugs for Hyperuricemia, an Update on Recent Developments. Expert Opinion on Investigational Drugs, 27, 437-444. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Strilchuk, L., Fogacci, F. and Cicero, A.F. (2019) Safety and Tolerability of Available Urate-Lowering Drugs: A Critical Review. Expert Opinion on Drug Safety, 18, 261-271. [Google Scholar] [CrossRef] [PubMed]
|